Guttate psoriasis looks like small red or pink patches that don’t always have scales on lighter skin tones. (Photo Credit: Dr. Harout Tanielian/Science Source) Guttate psoriasis is a type of ...

apremilast (Otezla) oral tablets, deucravacitinib (Sotyktu) oral TYK 2 inhibitor, or methotrexate (Otrexup (PF), Trexall Tablets, Xatmep). Phototherapy. Just like with guttate psoriasis ...

Otezla (apremilast) is a prescription drug that’s used to treat plaque psoriasis, psoriatic arthritis, and mouth sores related to Behçet’s disease in certain people. Otezla comes as an oral ...

Guttate psoriasis is a form of psoriasis that often appears in the wake of strep throat and other similar infections. It's characterized by the spontaneous outbreak of small, pink, teardrop-shaped ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

Otezla, a first-in-class treatment for plaque psoriasis has been approved in the US. Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its ...

Amgen has announced the availability of Otezla (apremilast) in the US for paediatric patients with moderate to severe plaque psoriasis, [a skin lesion condition]. It is the first and only pill for ...

Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ...

Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis. Otezla was approved earlier this year. Otezla is now available in the U.S. for the ...

That compared with 12.7% and 9.4% for those receiving placebo and 35.1% and 40.2% of patients on Otezla. PASI 75 is a measure on the psoriasis area and severity index. In other words, the overall ...